Critical Care

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Real Time Detection of Electrophysiologic Disturbances Following Subdural Hematoma Evacuation

   Rochester, Minn.

   The purpose of this study is to detect and characterizer electrophysiologic disturbances (such as local field potentials) in patients with underrecognized cause of coma, focal deficits and prolonged encephalopathy following subdural hematoma (SDH) evacuation.

2. COVID-19 Remote Monitoring

   Jacksonville, Fla.

   As a part of the COVID-19 pandemic, Mayo Clinic Florida is utilizing remote monitoring technology to monitor non-ICU patients in order to identify patients who will need the ICU and prevent crashing patients on the floor. MCF is using approved InTouch video and Biofourmis remote vital sign monitoring technology, both used by Mayo Clinic in other capacities. This study will not be a study of the efficacy or the accuracy of these devices as they are already incorporated as standard of practice. This study will assess the reduction of on floor crashing patients, quality of care, and satisfaction of providers by using this technology.  

3. COVID-19 and Acute Renal Failure

   Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla.

   The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).

    

    

    

4. Study to Compare Electrical and Ultrasonographic Evaluation of the Phrenic Nerve-Diaphragm Neuromuscular Junction (NMJ) Function

   Jacksonville, Fla.

   The purpose of this study is to ensure technical success in the treatment of assessing diaphragmatic neuromuscular junction (NMJ) function of the diaphragm in normal patients.

5. Development of Potential COVID-19 Vaccine and Serological Assay

   Rochester, Minn.

   Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody detectable targets on cancer cells (cancer vaccines or antibody guided therapeutics).  In this approach, we isolate and affinity-column immobilize the IgG fraction from patient serum before and after immune therapy for melanoma, and expose the immobilized antibodies to bacteriophage expressing approximately 2x109 overlapping cDNA sequences of paired (same patient derived plasma and cancer cells) melanoma genomic RNA.  Phage, expressing melanoma cDNA express the proteins/peptides on their capsid are “recognized” by the immobilized antibodies are retained in the column, and subsequently eluted for DNA sequencing.  Comparison of the DNA profiles of the eluted phage using pre-immunotherapy and post-immunotherapy patient sera will reveal emergence of new antibodies (post-immunotherapy gain of antibodies) against proteins of potential interest for melanoma targeting.  In the current proposal, we hypothesize that reacting COVID serum from patients that have recovered from COVID infection and compare to non-infected self-serum (if available) and control healthy volunteer serum (available in our lab) may identify protein targets that have developed as a result of the COVID infection and could be useful in the development of a COVID vaccine as well as a serologic test for anti-COVID immunity. 

6. A Study to Detect Non-convulsive Seizures with Single-channel Electroencephalogram (EEG)

   Rochester, Minn.

   The purpose of this study is to assess how accurately a portable single-channel EEG device (Epilog™ by Epitel) detects generalized non-convulsive seizures, and to determine the feasibility of use of this device in an acute setting such as the Emergency Department (ED).

7. A Study to Evaluate the Efficacy and Safety of Colchicine on Coronavirus SARS-CoV2 Positive Adults

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Rochester, Minn.

   This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 infection and have at least one high-risk criterion. Approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo tablets for 30 days.

8. Training of Physicians in Critical Care Ultrasonography (CCUS)

   Rochester, Minn.

   The purpose of this study is to assess the improvement in physician’s knowledge and skill sets in ultrasonography after the implementation of simulation-based educational program.  

9. A Study to Evaluate SOLIRIS® to Treat Participants with Coronavirus Disease 2019

   Rochester, Minn.

   Soliris, an effective and extensively studied terminal complement inhibitor with a well-established safety profile, is proposed as an emergency therapy for the treatment of participants who have a confirmed diagnosis of SARS-CoV-2 infection with a clinical presentation consistent with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome (ARDS). Soliris produces complete and sustained inhibition of C5-mediated terminal complement activity. It is hypothesized that treatment with Soliris could ameliorate COVID-19-induced lung injury, improve outcomes in participants with COVID-19 severe pneumonia, acute lung injury, or ARDS and, with supportive medical care, provide additional time for participants to recover.

10. A Study to Evaluate the Effectiveness of Merimepodib in Adult Patients with Advanced COVID-1

    Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Rochester, Minn.

    This study will evaluate the efficacy of merimepodib (MMPD) administered orally every eight hours (q8h) for 10 days in adult patients with advanced COVID-19.